Drug · Monoclonal Antibody

Panitumumab

CI-DRUG-00000454Explore in graph →NCIt C1857 CHEMBL1201827 CIViC Approved

Regulatory

Approvals (10)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory10 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as VECTIBIX (DIN 02308509) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 3, 2017	health-canada-dpd
CA Health Canada	—	Marketed in Canada as VECTIBIX (DIN 02308487) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 27, 2008	health-canada-dpd
CA Health Canada	—	Marketed in Canada as VECTIBIX (DIN 02308495) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	35	23	23	180	10	CA, EU, US	Sep 27, 2006	2000-04
Malignant Pancreatic Neoplasm	Phase3	Phase 3	4	3	1	10	0	—	—	2000-04
Malignant Colon Neoplasm	Phase3	Phase 3	2	1	2	15	0	—	—	2004-12
Malignant Esophageal Neoplasm	Phase3	Phase 3	0	0	1	9	0

Curated evidence

Clinical evidence (127)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–50 of 127 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E10
Irinotecan + Panitumumab

Clinical trials

Trials with this intervention (182)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 182 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	recruiting	Phase 2	2,900	National Cancer Institute (NCI)NIH	2	Sep 28, 2026	clinicaltrials
NCT06820463	A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: Epidermal growth factor receptor erbB1 inhibitor
Targets: 1 gene
UNII: 6A901E312A
Aliases: Abenix, ABX-EGF, ABX-EGF, Clone E7.6.3, ABX-EGF Monoclonal Antibody, E7.6.3, Human IgG2K Monoclonal Antibody, L01xc08, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Panitumumab, Vectibix, VECTIBIX

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (9)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01FE02	PANITUMUMAB
ATC (WHO)	L01XC08	Antineoplastic agents
DIN (Health Canada)

CDKN2A p16 Expression2
Panitumumab	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	3	accepted	EID696 In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab)… (full text at CIViC) PMID 23746666 · Vermorken et al., 2013 · Open in CIViC	civic
〃	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID753 p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone. PMID 23746666 · Vermorken et al., 2013 · Open in CIViC	civic

EGFR G465R2
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	submitted	EID7083 Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC) PMID 29196463 · Strickler et al., 2018 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	4	accepted	EID1058 An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic

EGFR K467T2
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	submitted	EID7087 Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC) PMID 29196463 · Strickler et al., 2018 · Open in CIViC	civic
Futuximab/Modotuximab Mixture + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1082 In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumum… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic